Changes in how follicular lymphoma is managed have led to substantial improvement in prognosis and over all survival for patients with the disease.
A high-risk group of patients with follicular lymphoma could benefit from a novel drug combination, according to a new study published in the Journal of Experimental Medicine.
Patients with AIDS-related lymphomas may face an increased risk of CNSi compared to other lymphomas. Researchers report that CNSi - identified at the time of an ARL diagnosis - does not appear to have an impact on overall survival. The vast majority of patients have stage IV disease at the time of presentation.
Patients with terminal forms of leukemia and lymphoma who have run out of treatment options could soon benefit from a new drug, which not only puts an end to chemotherapy and has virtually no side effects.
The phosphatidylinositol-3-kinase delta inhibitor idelalisib shows antitumor activity in patients with indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Peripheral T-cell lymphoma (PTCL) is a rare and aggressive form of cancer. This fact sheet explains the condition to newly diagnosed patients and provides sources of support.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|